English

Last day of trading in BTU

Report this content

In March 2018, Initiator Pharma A/S (“Initiator Pharma”) conducted a rights issue in which the public also were given the opportunity to subscribe for units. Through the rights issue, a total of 8.683.941 shares and a total of 5.789.294 share options of series TO 1 were issued. Last day of trading in BTUs (paid subscription unit) is April 26th, 2018 and stop date is April 30th, 2018.

A total of 8.683.941 shares and 5.789.294 share options of series TO 1 have been registered at the Danish Companies Registration Office (“Erhvervsstyrelsen”) and is estimated to be distributed to each VP account/depot on May 3rd, 2018. After the registration of the rights issue at Erhvervsstyrelsen, the total number of shares in Initiator Pharma will amount to 17.367.884 shares, the number of share options of series TO 1 will amount to 5.789.294 and the share capital will amount to DKK 1.823.627,82.

Financial advisor 

Sedermera Fondkommission has been the financial advisor to Initiator Pharma in connection with the rights issue of units.

For further information about the rights issue, please contact:

Sedermera Fondkommission

Telephone: +46 40-615 14 10

E-mail: info@sedermera.se

For further information about Initiator Pharma, please contact: 

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 

E-mail: ceo@initiatorpharma.com 

About Initiator Pharma

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for patients suffering from Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond to the current market PDE5i medications.Learn more at initiatorpharma.com.

About erectile dysfunction

Erectile dysfunction is characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of life style diseases such as diabetes. The large diabetic ED patient segment is often responding poorly to the current medication and is therefore of particular interest for Initiator Pharma. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, relationship problems etc. (Althof, 2002; Shabsigh et al., 1998, Tsai, 2008; Litwin et al., 1998).

This is an English translation of a press release originally drafted in Swedish. In the case of any discrepancies, the Swedish version shall prevail. 

Documents & Links